Clinical trials: Oral Cavity Carcinoma
Advanced Solid Tumors, Non-small Cell Lung Cancer
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans…
- Trial name
- NCT01625234
- Testing
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- Xcovery Holdings, Inc.
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Oral Cavity Cancer, Sinonasal Cancer
Radiotherapy of Head and Neck Cancer Using an Intraoral Stent
Radiotherapy of oral cavity cancer and sinonasal cancer is associated with acute and late morbidity. Use of an intraoral stent will provide a larger distance between the tongue and palate and can reduce side-effects.
- Trial name
- NCT04330781
- Testing
- Intraoral stent, No intraoral stent
- Where
- Norway
- Volunteers
- 220 people
- Sponsor
- Oslo University Hospital
Cancer of Liver
Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma
Our long-term working hypothesis is that if 3-D radiation is combined with the effect of capecitabine one hopes to see improved and durable tumor response and survival with acceptable toxicity.
- Trial name
- NCT00216437
- Testing
- Capecitabine (Xeloda)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- James A. Haley Veterans Administration Hospital
Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities…
- Trial name
- NCT01449461
- Testing
- Brigatinib
- Volunteers
- 137 people
- Sponsor
- Ariad Pharmaceuticals
Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Advanced Solid Tumor
- Trial name
- NCT04849273
- Testing
- TPX-0131
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 11 people
- Sponsor
- Turning Point Therapeutics, Inc.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00049283
- Testing
- erlotinib hydrochloride, docetaxel, radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002888
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- 87 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Xerostomia
Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia
The purpose of this study is to determine the effectiveness of cevimeline (versus placebo) on the oral health of patients who have dry mouth which was caused by radiation therapy that was given for treatment of head and/or neck…
- Trial name
- SMILE (NCT00466388)
- Testing
- Cevimeline
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- American Academy of Otolaryngology-Head and Neck Surgery Foundation
Oral Squamous Cell Carcinoma (OSCC)
Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma
This observational study will evaluate whether salivary interleukin-6 levels and selected interleukin gene polymorphisms are associated with regional lymph node involvement in patients with oral squamous cell carcinoma.
- Trial name
- IL6-OSCC (NCT07692360)
- Testing
- Saliva Collection and Biomarker Analysis
- Where
- 2 sites in Italy
- Volunteers
- 38 people
- Sponsor
- University of Pavia
Head and Neck Cancer
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment.
- Trial name
- NCT00896675
- Testing
- proteomic profiles
- Where
- 3 sites in United States
- Volunteers
- 352 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer (NSCLC), Elderly (People Aged 65 or More)
Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
The goal of this observational study is to evaluate the efficacy and safety of oral metronomic vinorelbine and PD-1 inhibitors in elderly patients with unoperable, locally advanced or metastatic non-small-cell lung cancer.
- Trial name
- NCT07041320
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Chest Hospital
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Non-Small Cell Lung Cancer
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer
The purpose of this study is to define the schedule and dose of oral vinorelbine (Navelbine) to be used with erlotinib in non-small cell lung cancer.
- Trial name
- NCT00702182
- Testing
- Vinorelbine (Navelbine), Erlotinib
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Radiation-Induced Oral Mucositis, Head &Amp; Neck Cancer
Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer
This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy.
- Conditions
- Radiation-Induced Oral Mucositis, Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
- Trial name
- RICE-MUC (NCT07242859)
- Testing
- rice bran
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Christina Milad Lobos
Ovarian Carcinoma
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
Preclinical studies showed that metronomic chemotherapy can induce tumor regression secondary to apoptosis of the tumor blood vessels. This effect was increased by combining metronomic chemotherapy with anti-angiogenic drugs.
- Trial name
- NCT01175772
- Testing
- Cytophosphan, Celecoxib, Methotrexate
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- HaEmek Medical Center, Israel
Primary Advanced Carcinoma of the Oral Cavity or Oropharynx, Squamous Cell Carcinoma of the Head and Neck
Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor
The primary goal of this study is to determine if the vaccine can be safely given to subjects, and to see what side effects occur (both good and bad) when they are given this experimental tumor vaccine.
- Trial name
- NCT00377247
- Testing
- autologous monocyte-derived dendritic cells (DC) transfected with DNA
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pittsburgh
Oral Cancer
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma
Investigate the role of SDF-1/CXCR4 in the metastasis of oral squamous cell carcinoma
- Trial name
- NCT00173849
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Cancer
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- CARIO (NCT00963326)
- Testing
- laboratory biomarker analysis
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Cancer
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00096174
- Testing
- cetuximab C225, cisplatin, radiation therapy
- Volunteers
- 69 people
- Sponsor
- Eastern Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.